Stifel Nicolaus Keeps Their Hold Rating on MacroGenics (MGNX)
Stifel Nicolaus analyst Stephen Willey reiterated a Hold rating on MacroGenics (MGNX) with a $4.00 price target. Willey, a 4-star analyst, has a 6.8% average return and a 43.83% success rate. MacroGenics also received a Hold rating from TR | OpenAI – 4o’s Dex Genotek, while Barclays maintained a Buy rating on the stock.
In a report released today, Stephen Willey from Stifel Nicolaus reiterated a Hold rating on MacroGenics, with a price target of $4.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Willey is a 4-star analyst with an average return of 6.8% and a 43.83% success rate. Willey covers the Healthcare sector, focusing on stocks such as Celcuity, Syndax Pharmaceuticals, and Nurix Therapeutics.
In addition to Stifel Nicolaus, MacroGenics also received a Hold from TR | OpenAI – 4o’s Dex Genotek in a report issued today. However, yesterday, Barclays maintained a Buy rating on MacroGenics (NASDAQ: MGNX).
